Transgene
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer. Our approach uses the mechanisms of the immune response to enable the patient’s body to fight against disease.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-19 08:00 |
Inside Information Statement
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial …
|
English | 310.5 KB | |
| 2025-06-19 08:00 |
Inside Information Statement
Transgene finalise la sélection initiale de patients pour la partie Phase II de…
|
French | 304.7 KB | |
| 2025-06-13 08:30 |
Inside Information Statement
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotec…
|
French | 304.7 KB | |
| 2025-06-13 08:30 |
Inside Information Statement
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
|
English | 277.0 KB | |
| 2025-06-03 08:00 |
Inside Information Statement
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les c…
|
French | 269.2 KB | |
| 2025-06-03 08:00 |
Inside Information Statement
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presente…
|
English | 282.5 KB | |
| 2025-06-01 19:15 |
Inside Information Statement
Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une…
|
French | 378.8 KB | |
| 2025-06-01 19:15 |
Inside Information Statement
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Re…
|
English | 394.4 KB | |
| 2025-05-22 17:45 |
Regulatory News Service
Transgene présente des données de survie sans récidive à 24 mois sur l’ensemble…
|
French | 378.1 KB | |
| 2025-05-22 17:45 |
Regulatory News Service
Transgene to Present 24-month Disease-Free Survival Data from All Patients in P…
|
English | 412.3 KB | |
| 2025-05-15 17:45 |
Inside Information Statement
Assemblée Générale Mixte de Transgene du 15 mai 2025
|
French | 315.4 KB | |
| 2025-05-15 17:45 |
Inside Information Statement
Transgene's Combined General Meeting of May 15, 2025
|
English | 285.9 KB | |
| 2025-04-24 17:45 |
Quarterly Report
Transgene Provides Business and Financial Update for Q1 2025
|
English | 310.4 KB | |
| 2025-04-24 17:45 |
Earnings Release
Transgene fait le point sur ses activités et sa situation financière au premier…
|
French | 452.4 KB | |
| 2025-04-24 08:00 |
General Meeting Notice
Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai…
|
French | 277.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
TME Pharma N.V. | Germany | ALTME | |
|
Toleranzia AB | Sweden | TOL | |
|
Tvardi Therapeutics Inc. | United States of America | TVRD | |
|
Ulisse Biomed | Italy | UBM | |
|
Univo Pharmaceuticals Ltd. | Israel | UNVO-M | |
|
Urteste S.A. | Poland | URT | |
|
Valbiotis | France | ALVAL | |
|
VALIRX PLC | United Kingdom | VAL | |
|
Vaxxa AB | Sweden | VAXXA | |
| Vision Sigma Ltd. | Israel | VISN |